ArticleInternational journal of clinical oncology2011
Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection.
Article in International journal of clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis.Medicine · 2017Pooled it
- The Impact of MetabolicMolecular imaging and radionuclide therapy · 2023Article
- Clinical Impact of Dual Time PointCancers · 2022Article
- Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual-center study.Annals of gastroenterological surgery · 2021Article
- Article
- Prognostic Implications of 18-FDG Positron Emission Tomography/Computed Tomography in Resectable Pancreatic Cancer.Journal of clinical medicine · 2020Article
- The efficacy ofAnnals of surgical treatment and research · 2020Article
- Early recurrence detected by 18F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma.Medicine · 2020Observational
- [EJNMMI research · 2019Article
- Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design.Academic radiology · 2017Review
- The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2016Article
- Multimodality treatment of recurrent pancreatic cancer: Mith or reality?World journal of gastrointestinal oncology · 2015Article
- Article
- The role of ¹⁸F-FDG PET imaging in upper gastrointestinal malignancies.Current treatment options in oncology · 2014Review
- Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer.World journal of surgery · 2013Article
- Article
- State-of-the-art PET/CT of the pancreas: current role and emerging indications.Radiographics : a review publication of the Radiological Society of North America, IncArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn important step in deciding the treatment strategy for pancreatic cancer is to preoperatively predict the possibility of early recurrence. We reviewed whether 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) before pancreatic cancer resection could predict tumor recurrence in the early postoperative period.
methodsFDG-PET/CT was performed preoperatively on 56 patients with pancreatic cancer. The maximum standardized uptake (SUV(max)) values obtained by FDG-PET/CT were compared between two groups: patients with and without recurrence within the first 6 postoperative months. SUV(max) analyses were also performed to determine whether age, sex, CA 19-9 values, the operative method, and portal vein resection were also predictive of recurrence within less than 6 months after tumor resection.
resultsThe median SUV(max) values of the recurrence group and no-recurrence group were 7.9 and 4.2, respectively (P = 0.0042). The SUV(max) was the only risk factor for recurrence in the first 6 postoperative months identified by multivariate analysis (P = 0.0062).
conclusionsPreoperative SUV(max) was higher in the recurrence group during the early postoperative period, and a high SUV(max) was a risk factor for early postoperative recurrence. Based on these results, we conclude that FDG-PET/CT is predictive of the recurrence of pancreatic cancer in the early postoperative period.
Indexed as
Identifiers
20862596What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.